| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | 0.0021 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.0047 | 0.9 |
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | JQ-1:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.0021 | 1 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0025 | 1 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.0085 | 1 |